Schroders Capital Global Innovation Trust plc - INOV (LON:INOV) Posts Quarterly Earnings Results

Key Points

• NAV per share increased 1.3% in the first half, while the share price rose 10.5%, reducing the discount to NAV from over 30% to about 25%.
• The managed wind-down generated £9.6 million in realizations, and the planned 2026 tender offer was increased to £28 million, bringing expected capital returned since the wind-down to £66 million.
• Management does not expect material portfolio realizations before 2028; minority ownership limits exit control, while Kymab’s milestone value was eliminated and Back Market and AgroStar were written down.

Schroders Capital Global Innovation Trust plc - INOV (LON:INOV - Get Free Report) released its earnings results on Wednesday. The company reported GBX (0.12) EPS for the quarter, Digital Look Earnings reports.

Here are the key takeaways from Schroders Capital Global Innovation Trust plc - INOV's conference call:

• NAV per share rose 1.3% in the first half, while the share price increased 10.5%, narrowing the discount to NAV from more than 30% to approximately 25%.
• The managed wind-down generated £9.6 million in realizations, including exits from Bluewater Bio, Autolus Therapeutics and milestone proceeds. The planned 2026 tender offer was increased to £28 million, taking expected capital returned since the wind-down to £66 million.
• The life sciences portfolio produced key trade-sale outcomes: Memo Therapeutics’ lead program was acquired by Ipsen for £200 million upfront plus potential milestones, while Neurona Therapeutics was acquired by UCB for $650 million upfront plus potential milestones.
• Revolut remained a major value driver, with management highlighting 30% customer growth to 68 million, strong profitability and continued regulatory expansion. Its increased valuation made it the fund’s second-largest holding, close behind Atom Bank.
• Management said it does not expect material portfolio realizations before 2028, reflecting limited control over exits from minority investments and dependence on trade sales or IPOs. In addition, Kymab’s milestone value was eliminated after Sanofi discontinued the relevant program, while Back Market and AgroStar were written down.

Schroders Capital Global Innovation Trust plc - INOV Stock Performance

Shares of LON:INOV opened at GBX 17.62 on Wednesday. The company has a market capitalization of £111.96 million, a PE ratio of 7.83 and a beta of 0.54. The stock has a fifty day moving average of GBX 17.09 and a 200-day moving average of GBX 15.97. Schroders Capital Global Innovation Trust plc - INOV has a one year low of GBX 12.70 and a one year high of GBX 18.01.

About Schroders Capital Global Innovation Trust plc - INOV

Schroder UK Public Private Trust plc specializes in investments in startups, midsize, middle market and large stage, early stage and mature stage investments. The fund primarily invests in the healthcare, financials, industrials, technology, consumer goods, telecommunications, basic materials, and biotechnology sector. It seeks to invest in quoted and unquoted companies. It primarily invests in companies incorporated in the United Kingdom or traded on a London Stock Exchange market but can invest in Europe, United States and Asia other countries.